ERBB2 and breast carcinoma: On the other hand, although the overexpression of Her-2 (human epidermal growth factor receptor-2) is associated with patients’ worse prognosis (1), recently developed drugs for targeted therapy and combination of trastuzumab with chemotherapy are introduced as effective treatments for patients with Her-2 positive breast cancers (12,13).